摘要
目的研究CD56抗原表达与急性早幼粒细胞白血病(Acute Promyelocytic Leukemia,APL)复发的相关性,为APL复发高危患者治疗提供参考。方法对100例确诊为APL的患者采用流式细胞术检测CD56的表达,均采用维甲酸联合蒽环类药物治疗,每3月进行骨髓检验,评价疾病缓解及复发情况。结果 100例患者中CD56阳性表达27例,阴性表达73例;阳性组复发率为29.63%,高于阴性组的5.48%(P<0.05);阳性组外周白细胞计数水平高于阴性组(P<0.01);骨髓PML-RARA融合基因r型所占比例高于阴性组(P<0.05);阳性组正常核型所占比例低于阴性组(P<0.05)。结论 CD56抗原阳性表达的APL患者易复发,预后较差;CD56抗原可作为APL复发的预测指标。
Objective To understand the correlation of the expressions of CD56 antigen to the relapse of acute promyelocytic leukemia（APL） and develop an effective medicine the relapse of the disease. Method Flow cytometry was employed to detect the expressions of CD56 of 100 patients diagnosed as cases of APL. All cases were treated with retinoic acid and anthracycline. Samples of bone marrow were taken and subjected to examination bone every 3 months, and disease remission and recurrence were monitored regularly. Findings The expressions of 27 cases were detected to be positive, and the expressions of 73 cases negative; the recurrence rate of the positive group was 29.63% , higher than the negative group 5.48% （P 〈 0.05 ） ; peripheral white blood cell count （WBC） of the positive group appeared higher than that of the negative group（P 〈 0.05 ） ; Bone marrow PML-RARA fusion gene r-type proportions of the positive group appeared higher than that of the negative group （ P 〈 0.05 ） ; the normal karyotype of the positive group appeared lower than that of the negative group（P 〈0.05 ）. Conclusion APL tends to relapse in patients whose CD56 antigen expressions detected to be positive. The prognosis for patients as such was poor. The expressions of CD56 antigen can be referred to as a precursor in determining the relapse of APL.
出处
《健康研究》
CAS
2013年第5期345-347,共3页
Health Research
基金
2012瑞安市第四批科技计划项目(201204030)
